» Articles » PMID: 36830231

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma

Overview
Specialty Pharmacology
Date 2023 Feb 25
PMID 36830231
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Piperacillin (Pip)/tazobactam (Taz) is a broad-spectrum antimicrobial agent that has been commonly used in the intensive care unit for severe and life-threatening infections. Recent evidence suggests that therapeutic drug monitoring (TDM) for Pip could be beneficial in clinical practice to facilitate dose optimization and increase the odds of treatment success. The aim was to develop and validate a sensitive and simple high-performance liquid chromatography (HPLC) method for the simultaneous quantification of Pip and Taz in human plasma.

Methods: Samples (0.3 mL) were deproteinized with acetonitrile. The supernatant was evaporated and then reconstituted and injected into the HPLC. The chromatographic analysis was carried out by using the C18 column and gradient elution with the acetonitrile:water mobile phase mixture with 0.1% trifluoracetic acid at a flow rate of 0.8 mL/min using a UV detector at 218 nm.

Results: The method had acceptable linearity (r > 0.99) over the concentration ranges of 0.5-400 μg/mL and 1-100 μg/mL for Pip and Taz, respectively. The method demonstrated acceptable inter- and intra-day precision and accuracy within ±20% with adequate stability results.

Conclusion: The developed method is sensitive and simple and utilizes simple sample preparation and elution steps, making it suitable and practical for Pip/Taz TDM.

Citing Articles

Preanalytical Stability of 13 Antibiotics in Biological Samples: A Crucial Factor for Therapeutic Drug Monitoring.

Dalla Zuanna P, Curci D, Lucafo M, Addobbati R, Fabretto A, Stocco G Antibiotics (Basel). 2024; 13(7).

PMID: 39061358 PMC: 11274111. DOI: 10.3390/antibiotics13070675.


Development of an eco-friendly capillary electrophoresis method for the simultaneous determination of piperacillin, tazobactam and ibuprofen in plasma samples: application to a pharmacokinetic study in rats.

Othman W, Al-Zoman N, Darwish I, Almomen A, Saad S, Abdallah F RSC Adv. 2024; 14(32):23378-23391.

PMID: 39049887 PMC: 11267906. DOI: 10.1039/d4ra04615c.

References
1.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B . Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2002; 345(19):1368-77. DOI: 10.1056/NEJMoa010307. View

2.
Hefny F, Stuart A, Kung J, Mahmoud S . Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14(2). PMC: 8878755. DOI: 10.3390/pharmaceutics14020445. View

3.
Kim M, Capitano B, Mattoes H, Xuan D, Quintiliani R, Nightingale C . Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy. 2002; 22(5):569-77. DOI: 10.1592/phco.22.8.569.33209. View

4.
Hefny F, Sambhi S, Morris C, Kung J, Stuart A, Mahmoud S . Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance. Eur J Drug Metab Pharmacokinet. 2022; 47(5):607-620. DOI: 10.1007/s13318-022-00779-4. View

5.
Luther M, Timbrook T, Caffrey A, Dosa D, Lodise T, LaPlante K . Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2017; 46(1):12-20. DOI: 10.1097/CCM.0000000000002769. View